Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by NovAccess Global Inc.
CORRECTION: NovAccess Global Announces Filing of Orphan Drug Application for TLR-AD1
July 19, 2022
From
NovAccess Global Inc.
Via
AccessWire
Tickers
XSNX
NovAccess Global Announces Filing of Orphan Drug Application for TLR-AD1
July 19, 2022
From
NovAccess Global Inc.
Via
AccessWire
Topics
Intellectual Property
Tickers
XSNX
NovAccess Global CEO Dwain Irvin Featured on MoneyTV
June 14, 2022
From
NovAccess Global Inc.
Via
AccessWire
Tickers
XSNX
NovAccess Global to Participate in LD Micro Invitational XII Conference
May 19, 2022
From
NovAccess Global Inc.
Via
AccessWire
Topics
Intellectual Property
Tickers
XSNX
NovAccess Global Stock Redemption and Expanded Board of Directors Reinforces Shareholder Value and Positions the Company to Accelerate Objectives
March 17, 2022
From
NovAccess Global Inc.
Via
AccessWire
Tickers
XSNX
NovAccess Global, Inc.'s CEO to attend BIO Conference in New York
February 15, 2022
From
NovAccess Global Inc.
Via
AccessWire
Topics
Intellectual Property
Tickers
XSNX
NovAccess Global, Inc. Names Neil Laird, Chief Financial Officer
December 08, 2021
From
NovAccess Global Inc.
Via
AccessWire
Topics
Retirement
Tickers
XSNX
NovAccess Global, Inc. Expands Advisory Board
October 06, 2021
From
NovAccess Global Inc.
Via
AccessWire
Tickers
XSNX
NovAccess Global, Inc. CEO Interviewed On MoneyTV
September 15, 2021
From
NovAccess Global Inc.
Via
AccessWire
Tickers
XSNX
NovAccess Global, Inc. to Present at the Prestigious Society for Brain Mapping and Therapeutics 2021 World Congress
July 08, 2021
From
NovAccess Global Inc.
Via
AccessWire
Tickers
XSNX
NovAccess Global, Inc. Announces Successful Completion of Pre-IND Meeting with FDA
June 29, 2021
From
NovAccess Global Inc.
Via
AccessWire
Tickers
XSNX
NovAccess Global Readies for Development of Novel Immunotherapies for Brain Tumor Patients with pre-IND meeting scheduled with the FDA and Files Form 10-K for Fiscal 2020 and Form 10-Q for FQ1/FQ2, 2021
June 08, 2021
From
NovAccess Global Inc.
Via
AccessWire
Topics
Intellectual Property
Tickers
XSNX
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit